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Abstract. Preeclampsia (PE) is a pregnancy-related disease with 
potentially severe consequences with respect to foeto-maternal 
morbidity and mortality. However, the molecular pathogenesis 
of PE remains largely unknown. Recent reports have shown 
that microRNAs (miRNAs or miRs) may play important roles 
in the development of PE. Analysing the miRNAs in sera from 
preeclamptic women may improve our understanding of the 
pathophysiological mechanisms of the disease. The aim of 
this retrospective study was to identify whether circulating 
miRNAs were differentially expressed in PE patients compared 
with controls. Serum samples from 23 women who developed 
PE were compared with samples from 44 pregnant controls. 
Seventeen circulating miRNAs previously described in PE were 
chosen for evaluation of their expression by reverse transcrip-
tion quantitative polymerase chain reaction (RT-qPCR). In the 
maternal serum, the miR-210-3p, miR-210-5p, miR-1233-3p, 
and miR‑574‑5p levels were found to be significantly higher in 
the PE patients than in the controls (P<0.05). Using a logistic 
regression model, we evaluated the discriminant power of 
those differentially expressed miRNAs, and the combination 
of miR-210-5p and miR-574-5p yielded an area under the curve 
of 0.7223 for discriminating PE patients from the controls. In 
conclusion, the fact that four circulating miRNAs (miR-210-3p, 
miR-210-5p, miR-1233-3p, and miR-574-5p) were differentially 
expressed in the sera of women who developed PE compared 
with controls confirms the possible pathophysiological role of 
miRNAs in PE.
Introduction
Preeclampsia (PE) is a pregnancy‑specific syndrome associ-
ated with hypertension and proteinuria or thrombocytopenia, 
renal insufficiency, impaired liver function, pulmonary 
oedema, cerebral symptoms, and visual symptoms (1). PE 
affects 2-5% of pregnancies worldwide (2-4). It can lead to 
severe maternal and perinatal morbidity, including uterine 
growth restriction and prematurity. PE is responsible for 
an elevated perinatal mortality rate and causes 10-15% of 
maternal deaths (3,5).
The placenta plays a key role in the initiation and 
progression of the disorders caused by PE (6). As commonly 
described, PE has a combined genetic, immune, and angio-
genic aetiology. The origin of PE seems to be the impaired 
invasion of maternal spiral arteries by trophoblast cells in the 
context of local abnormal immune interactions between the 
fetoplacental unit and mother (7-9). Placental underperfu-
sion induces a chronic hypoxic state (10). Combined with the 
reoxygenation that occurs, it creates increased local oxidative 
stress, resulting in apoptosis and necrosis of the placenta. 
Placental pro-inflammatory and antiangiogenic mediators 
and apoptotic bodies, released in the maternal circulation, 
cause maternal systemic endothelial cell dysfunction and 
systemic inflammation (5,11). Although several hypotheses 
have been suggested to explain this vascular, multi-systemic 
pregnancy-related disease, its complete pathogenesis remains 
poorly understood (12,13), and PE prevention, diagnosis, and 
treatment remain an important challenge.
MicroRNAs (miRNAs or miRs) are small non-coding 
RNAs (20-24 nucleotides) that regulate gene expression 
through post-transcriptional repression or degradation of 
messenger RNA (14,15). miRNAs are present in animals and 
plants and have been detected in several human fluids (16). 
They are critical in many biological processes, including 
the regulation of cell differentiation, proliferation, apoptosis, 
angiogenesis, and metabolism (17). Specific plasma‑related 
miRNAs were identified in maternal plasma or serum in 
normal pregnancies, as well as in pathological pregnancy 
conditions, such as PE (18,19). Several recent reports described 
the significant dysregulation of specific miRNA expression in 
the maternal circulation of PE patients compared with controls 
(miR-24, miR-26a, miR-29a, miR-103, miR-130b, miR-141, 
miR-144, miR-152, miR-181a, miR-210, miR-342-3p, miR-520, 
miR-574-5p, and miR-1233) (20-23).
We hypothesized that the expression levels of specific 
miRNAs in maternal blood could be dysregulated before 
the onset of PE and be used to enhance screening, diagnosis, 
or prognosis. We aimed to analyse, in a case-control study, 
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several miRNAs that were previously described as differen-
tially expressed in PE.
Materials and methods
miRNA selection. After performing a review on PubMed until 
26 February, 2015, using the key words, ‘miRNA, pregnan-
cies, preeclampsia, placenta, circulating’, and consulting the 
miRNA database, 17 miRNAs were selected (Table I).
Study population. In this retrospective study, 67 preg-
nant women, aged 19-44 years, with a gestational age of 
24-36 weeks and 6 days of amenorrhea, were selected among 
a prospective cohort of pregnant women presenting, at 24 
to <37 weeks' gestation, clinical suspicion of, but not mani-
festing preeclampsia/eclampsia/HELLP syndrome. Suspicion 
of PE was assessed on the basis of the following criteria: 
New elevation of blood pressure (<140/90 mmHg), with or 
without pre-existing essential hypertension; de novo or major 
proteinuria (<30 mg/dl or <2+ on a urine dipstick); and clinical 
(epigastric pain, headache, visual disturbances, and excessive 
weight gain), biological (thrombocytopenia or elevation of 
transaminases), and ultrasonic (intrauterine growth restric-
tion, elevation of the uterine artery pulsatility index, or uterine 
artery notch) characteristics favouring PE. Manifestation of 
PE at selection was an exclusion criterion.
In each patient presenting with the aforementioned 
signs and symptoms who agreed to participate, blood was 
collected and further pregnancy follow-up was performed. 
Retrospectively, the PE and control cohorts were defined based 
on the diagnosis of PE at delivery.
The present study was approved by the Ethics Committee 
of the CHR Citadelle Hospital, Liège, Belgium, and informed 
consent was obtained from all the patients.
Sample collection. Blood samples were immediately centri-
fuged at 1,000 x g for 15 min, and sediment-free serum samples 
were collected. The serum aliquots were frozen at ‑80˚C until 
further analysis and were thawed only once thereafter.
miRNA extraction. Total RNA, including miRNA, was 
extracted from 200 µl of serum using the miRNeasy 
Serum/Plasma kit (Qiagen; Hilden, Germany) according to 
the manufacturer's instructions, and it was then eluted in 30 µl 
of nuclease-free water. A synthetic spike-in control miRNA 
(C. elegans miR-39 mimic, Qiagen) was added for subsequent 
normalisation.
Quantitative polymerase chain reaction (qPCR) for miRNAs. 
Total miRNA (2 µl) from each sample was reverse-transcribed 
with the miScript II TR kit (Qiagen) according to the manufac-
turer's instructions. The miRNAs were subsequently quantified 
using the miScript SYBR‑Green PCR kit (Qiagen) and specific 
forward primers. The reaction mixture included 2.5 µl of 
cDNA, 12.5 µl of QuantiTect SYBR-Green PCR Master Mix 
(Qiagen), 2.5 µl of forward primer, 2.5 µl of miScript Universal 
Primer (Qiagen), and 5 µl of RNase-free water for a final 
reaction volume of 25 µl. The thermal cycling consisted of an 
initial denaturation at 95˚C for 15 min, followed by 45 cycles at 
95˚C for 15 sec, 55˚C for 30 sec, and 70˚C for 30 sec.
The reactions were run in duplicate. Threshold cycle (Cq) 
and melting curves were acquired using the quantification and 
melting curve programs of the LightCycler® 96 Real-Time 
System (Roche Diagnostics GmbH, Mannheim, Germany). 
U6 small nuclear RNA (RNU6) and c-miR-39 were used 
to determine relative miRNA expression with the 2-ΔCq 
method (24‑26). The miRNA‑specific primer sequences are 
listed in Table Ι.
Statistical analysis. Quantitative parameters are presented 
as the means ± standard errors or medians. The statistical 
significance of differences in the expression levels of serum 
miRNAs between PE patients and controls was determined by 
the non-parametric Mann-Whitney U-Wilcoxon test. To deter-
mine the diagnostic accuracy of the miRNA expression levels, 
we generated receiver operating characteristic (ROC) curves 
and calculated the area under the ROC curves (AUC) (27). An 
evaluation of the diagnostic power of multiple combinations 
of the miRNA serum levels was performed using a logistic 
regression model. For all the statistical analyses, we used the 
statistics toolbox of Matlab R2024a software (MathWorks 
Inc., Natick, MA, USA). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Clinical characteristics. Table II shows the main features 
of the patients in each group. The median of gestational 
ages at inclusion (min-max) of the pregnant women were 
32.1 (25.3-36.6) (PE patients) and 31.1 (24.3-36.5) weeks 
(controls). There were no significant differences between 
the subjects and controls with respect to gestational age, 
maternal age, body mass index, smoking status, parity, 
gestity, ethnicity, personal and family history of PE, previous 
hypertension, proteinuria, and mean uterine artery pulsatility 
index. The median of gestational ages (min-max) at delivery 
were 36.4 (30.0-39.3) (PE patients) and 39.1 (35.2-41.3) weeks 
(controls) (P<0.0001).
Differential expression of circulating miRNAs. The expres-
sion levels of the 17 miRNAs (miR-16-2-3p, miR-24-3p, 
miR-26a-5p, miR-29a-3p, miR-124-3p, miR-130b-5p 
miR-130b-3p, miR-144-3p, miR-155-5p, miR-181a-3p, 
miR-181a-5p, miR-210-3p, miR-210-5p, miR-342-3p, 
miR-574-5p, miR-1233-3p, and miR-1233-5p) from the serum 
samples in the two groups (PE patients and controls) were 
analysed with reverse transcription quantitative polymerase 
chain reaction (RT-qPCR). According to RT-qPCR analysis, 
there was a significant upregulation of 4 miRNAs: miR‑210‑3p, 
miR-210-5p, miR-1233-3p, and miR-574-5p, in the serum of PE 
patients compared with controls (P<0.05) (Table III, Fig. 1).
Assessment of the screening value of circulating miRNAs in 
PE. We constructed and examined the ROC curves of the 
4 miRNAs that were upregulated in PE serum to evaluate 
their potential utility as biomarkers (Fig. 2). The AUCs of 
miR-210-3p, miR-210-5p, miR-1233-3p, and miR-574-5p were 
0.7090 [95% confidence interval (CI), 0.582‑0.836], 0.7040 
(95% CI, 0.568-0.840), 0.673 (95% CI, 0.543-0.803), and 0.710 
(95% CI, 0.578-0.842), respectively (Table IV). To improve the 
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diagnostic power of the miRNA expression levels, we applied 
a logistic regression model to the data from PE patients and 
controls. Different combinations were added to the model, and 
a maximum AUC of 0.7223 was found for miR-210-5p and 
Table II. Demographic and clinical characteristics of controls and preeclamptic (PE) pregnancies.
Characteristics Controls (n=44) PE (n=23) P-value
Maternal age (years) 30 (19-38) 29 (19-44) 0.82701
Gestational age at inclusion (weeks) 31.1 (24.3-36.5) 32.1 (25.3-36.6) 0.51313
Gestational age at delivery (weeks) 39.1 (35.2-41.3) 36.4 (30.0-39.3) <0.0001
Body mass index 27.2 (16.1-39.30) 27.40 (19-41.5) 0.85331
Gestity 2 (1-6)  2 (1-7) 0.19814
Parity 1 (0-5)  0 (0-3) 0.13570
Smoking status
  Previous smokers 6 (13.6%) 3 (13%) 0.66976
  Smokers 4 (9%) 3 (13%) 
Previous HTA 3 (6.8%) 2 (8.7%) 0.79403
Family history of PE 7 (16%) 6 (26%) 0.31431
Proteinuria 36 (81.8%) 19 (82.6%) 0.68365
Mean artery pulsatility index  0.77 (0.36-1.50) 0.86 (0.37-1.88) 0.27001
Systolic blood pressure (mmHg) 129 (105-160) 134 (120-159) 0.01763
Diastolic blood pressure (mmHg) 80 (60-100) 85 (70-100) 0.01551
Values are presented as median (min-max) or numbers (percentage). Statistical analyses were performed by the Mann-Whitney U-Wilcoxon 
test.
Table I. Primers used in quantitative PCR.
miRNA miRBase Reference Qiagen      Sequence of primer (5'-3')
hsa-miR-144-3p MIMAT0000436 MS00020328 TACAGTATAGATGATGTACT
hsa-miR-29a-3p MIMAT0000086 MS00003262 TAGCACCATCTGAAATCGGTTA
hsa-miR-210-3p MIMAT0000267 MS00003801 CTGTGCGTGTGACAGCGGCTGA
hsa-miR-210-5p MIMAT0026475 MS00045836 AGCCCCTGCCCACCGCACACTG
hsa-miR-1233-3p MIMAT0005588 MS00008512 TGAGCCCTGTCCTCCCGCAG
hsa-miR-1233-5p MIMAT0022943 MS00045213 AGTGGGAGGCCAGGGCACGGCA
hsa-miR-24-3p MIMAT0000080 MS00006552 TGGCTCAGTTCAGCAGGAACAG
hsa-miR-26a-5p MIMAT0000082 MS00029239 TTCAAGTAATCCAGGATAGGCT
hsa-miR-130b-3p MIMAT0000691 MS00003451 CAGTGCAATGATGAAAGGGCAT
hsa-miR-130b-5p MIMAT0004680 MS00008610 ACTCTTTCCCTGTTGCACTAC
hsa-miR-181a-5p MIMAT0000256 MS00008827 AACATTCAACGCTGTCGGTGAGT
hsa-miR-181a-3p MIMAT0000270 MS00006692 ACCATCGACCGTTGATTGTACC
hsa-miR-342-3p MIMAT0000753 MS00004011 TCTCACACAGAAATCGCACCCGT
hsa-miR-574-5p MIMAT0004795 MS00043617 TGAGTGTGTGTGTGTGAGTGTGT
hsa-miR-16-2-3p MIMAT0004518 MS00008813 CCAATATTACTGTGCTGCTTTA
hsa-miR-124-3p MIMAT0000422 MS00006622 TAAGGCACGCGGTGAATGCC
hsa-miR-155-5p MIMAT0000646 MS00031486 TTAATGCTAATCGTGATAGGGGT
c-miR-39 MIMAT0000010 MS00019789 TCACCGGGTGTAAATCAGCTTG
RNU6-2  MS00033740 
RNU6, U6 small nuclear RNA; hsa, Homo sapiens; c, Caenorhabditis elegans.
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miR-574-5p (Fig. 3). The fitted logistic regression model is as 
follows:
where P(Y=1) is the probability that the sample is a 
preeclamptic sample.
Discussion
Recently, the aberrant expression of miRNAs has been docu-
mented in different pregnancy-related conditions, such as 
PE, ectopic pregnancy, gestational diabetes mellitus, small 
for gestational age, recurrent pregnancy loss, and preterm 
delivery (28). These findings may be useful to improve our 
Figure 1. miRNAs differentially expressed in the sera of control pregnant women (NP) and preeclamptic women (PE). The expression of levels of miR-210-3p, 
miR-210-5p, miR-1233-3p and miR-574-5p were higher in preeclamptic women. Data are presented by box-and-whisker plots. Boxes indicate the 25th and 75th 
percentiles. The solid line within the box indicates the median value. *P<0.05 and **P<0.001.
Table III. Circulating miRNA expression levels in controls and preeclamptic pregnancies.
miRNA Controls (n=44) PE (n=23) P-value (Wilcoxon)
miR-210-3p 2.25±0.51 4.10±1.30 0.005
miR-210-5p 5.46±1.78 9.18±2.00 0.006
miR-1233-3p 3.73±0.96 4.97±0.98 0.021
miR-574-5p 2.47±0.59 5.84±1.30 0.005
miR-144-3p 2.47±0.49 3.56±1.05 0.187
miR-29a-3p 2.84±0.46 2.85±0.30 0.129
miR-1233-5p 3.23±0.86 2.91±0.42 0.129
miR-24-1-3p 2.99±0.46 3.15±0.35 0.088
miR-26a-5p 2.63±0.36 2.41±0.33 0.736
miR-130b-3p 3.55±0.69 3.22±0.40 0.352
miR-130b-5p1 4.39±0.87 4.92±0.92 0.113
miR-181a-5p 2.04±0.27 2.27±0.32 0.222
miR-181a-3p 2.63±1.17 2.28±0.61 0.113
miR-342-3p 3.06±0.39 3.18±0.34 0.282
miR-16-2-3p 2.14±0.36 3.27±0.90 0.124
miR-124-3p 3.51±0.72 2.97±0.35 0.362
miR-155-5p 3.58±0.62 3.76±0.65 0.402
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understanding of the underlying pathophysiology of these 
conditions.
In the present study, we confirmed the differential expres-
sion of several miRNAs that were identified in previous 
studies (20-23). Of the 17 miRNAs selected, miR-210-3p, 
miR-210-5p, miR-1233-3p, and miR-574-5p were upregulated 
in the sera of women who later developed PE compared with 
the controls who did not develop PE according to RT-qPCR. 
By performing logistic regression analysis of the differen-
tially expressed miRNAs, we found that the combination of 
miR-210-5p and miR-574-5p had the best diagnostic power 
with an AUC of 0.7223.
In our selection of miRNAs based on the data published 
in previous studies, we found very little overlap between the 
reported studies. This may be due to differences in the sample 
collection (sera versus plasma) or methods used for the analyses 
(RT-qPCR versus microarrays). Even results obtained from 
the same platform using products from different companies 
may be responsible for this low correlation of results (29,30). 
RT-qPCR is often considered as the ‘gold standard’ for the 
detection and quantification of gene expression. As a result, we 
chose to validate previously identified miRNA results using 
this procedure. However, one important step of RT-qPCR is 
normalisation of the miRNA expression level. Using improper 
reference genes for normalisation can result in evaluation bias 
during data analysis. To the best of our knowledge, there has 
been no consensus regarding a reliable housekeeping miRNA 
for analysing circulating miRNAs. Therefore, it becomes diffi-
cult to directly compare the results from different studies. In 
the present study, we used a double normalisation procedure, 
including the use of the synthetic c-miR-39 and RNU6B. 
The same amount of c-miR-39 was added to each sample 
before the extraction procedure, and the c-miR-39 expression 
level reflected differences at the same time in the extraction, 
reverse transcription, and PCR amplification procedures (31). 
Figure 2. Receiver operating characteristic (ROC) curves of different microRNAs.
Table IV. ROC results for several miRs.
 Area under the 95%  
miRs ROC curve (SE) CI P-value
miR-210-3p 0.7090 (0.06496) 0.5816-0.8363 0.005
miR-210-5p 0.7041 (0.06918) 0.5684-0.8397 0.006
miR-1233-3p 0.6729 (0.06632) 0.5429-0.8029 0.021
miR-574-5p 0.7100 (0.06717) 0.5783-0.8417 0.005
CI, confidence interval; SE, standard error; miRs, microRNAs.
Figure 3. Receiver operating characteristic (ROC) curves of combined 
microRNAs. Logistic regression model.
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However, the use of RNU6B complements technical bias with 
biological bias. Although RNU6B does not necessarily repre-
sent the ‘best’ reference, it has been previously used to analyse 
miRNAs in the sera of preeclamptic women (23,32).
The selection of the patients included in different studies 
may also introduce some bias. To identify new biomarkers 
for PE, a common strategy is to analyse a few samples or a 
pool of samples when performing miRNA profiling. This 
step is further followed by a validation procedure, frequently 
RT-qPCR, with additional samples from PE cases and 
controls. Usually, the second step does not completely validate 
the profiling step (18,20,21). Thus, in order to evaluate previ-
ously differentially reported miRNAs in PE, we performed a 
case-control study with 23 PE patients and 44 controls. The 
two groups were found to be comparable with respect to their 
maternal age, gestational age at inclusion, gestity, and parity. 
However, the retrospective nature of the investigation was one 
limitation of the study. A second limitation is that we were 
unable to separately analyse early- and late-onset PE due to 
the small sample size.
There is currently no consensus regarding a set of 
differentially expressed miRNAs in PE that may be used as 
biomarkers. Our approach was to collect several potentially 
interesting miRNAs that were previously described in the 
literature and test them in our set of case-control samples.
Notably, miR-210, which is one of the more commonly 
recurring miRNAs overexpressed in PE (22,32-36), was also 
elevated in our PE cohort. This particular miR-210 has been 
identified as a hypoxia‑induced miRNA in many cell types 
and tissues and is consistently upregulated by hypoxia in both 
physiological and malignant conditions (37,38). Several target 
genes with roles in mitochondrial metabolism, angiogenesis, 
and DNA repair have been identified, and most of them may 
be involved in the pathogenesis of PE. However, it remains 
unclear whether the differential expression of miR-210 is 
the consequence or origin of PE even though this particular 
miRNA has been described as a serum biomarker for PE (32).
There was also a higher level of circulating miR-1233 in the 
group of women who developed PE compared with the group of 
women with a normal pregnancy. Our results confirmed those 
of Ura et al (23), who were the first researchers to identify a 
potential role for miR-1233, which has already been described 
in renal carcinoma, in predicting PE. It is important to note 
that both miR-1233 and miR-210, which are upregulated in 
PE, are also upregulated in renal cell carcinoma. Of note, in 
patients with renal cell carcinoma, only miR-1233 was found 
to be increased (39). Information on the function of miR-1233, 
located on chromosome 15q14, is incomplete. Several potential 
target genes have been predicted using TargetScan 6.0 (40), 
but they have not been validated. The expression level of 
miR-574-5p was also elevated in the blood of women with 
PE (21). However, the expression of miR-574-5p has been 
poorly investigated.
Although there are many studies on PE screening, a 
biologically predictive and prognostic test with high accuracy 
for routine clinical use has yet to be identified (41‑43). The 
most promising strategies are multiparametric approaches that 
include a combination of maternal factors, biophysical tests 
(mean blood pressure, uterine artery Doppler), and biochemical 
markers (44-50). Sequential multiparametric testing is superior 
to screening in the first trimester alone (51). Nevertheless, a 
panel of tests is necessary to effectively identify women early 
in pregnancy who are at the highest risk for developing PE.
Although the prevalence of PE is relatively low and miRNA 
analysis is technically challenging, further studies with larger 
cohorts are mandatory. Discriminating between the different 
phenotypes of PE is also important because they may involve 
different sets of miRNA expression.
Furthermore, patients were sampled before the onset of 
PE and delivery (mean:one month before). Indeed, cases were 
enrolled when there was suspicion of PE, but manifest PE was 
an exclusion criterion. This protocol may partially explain the 
reason for only 4 of the 17 selected miRNAs being signifi-
cantly upregulated.
The fact that four circulating miRNAs (miR-210-3p, 
miR-210-5p, miR-1233-3p, and miR-574-5p) were differen-
tially expressed in the sera of women who later developed PE 
compared with women who did not develop PE, confirms the 
possible pathophysiological role of miRNAs in PE, as previ-
ously suggested (19,52,53). Particularly, exploring the role of 
miR-1233 and miR-574 in PE could enrich our understanding 
of this disease.
Future research on the biological pathway of circulating 
miRNAs may enhance our understanding of the pathogen-
esis of PE and aid in the development of new biomarkers for 
clinical application. Using these miRNAs in a multiparametric 
test may also provide a new clinical strategy for identifying 
women who are at risk for developing PE.
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